Ken Griffin Foghorn Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$5.05 - $8.0 $8,585 - $13,600	-1,700 Reduced 22.37%	5,900 $33,000
Q1 2024 May 15, 2024	BUY	$2.82 - $7.94 $21,432 - $60,344	7,600 New	7,600 $50,000
Q1 2023 May 15, 2023	SELL	$4.66 - $8.99 $181,740 - $350,610	-39,000 Reduced 98.73%	500 $3,000
Q4 2022 Feb 14, 2023	BUY	$5.44 - $9.46 $7,072 - $12,298	1,300 Added 3.4%	39,500 $252,000
Q3 2022 Nov 14, 2022	BUY	$7.52 - $18.01 $287,264 - $687,982	38,200 New	38,200 $328,000

32.8M

1.8K

Ticker FHTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,637,400
Market Cap $390M
Description
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.